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Introduction
Arginine is a naturally occurring basic amino acid, that is
involved in a large number of important protein-protein and
protein-nucleic acid interactions. The ability of the protonated
side chain of arginine to form hydrogen bonds and “salt bridges”
with aspartic and glutamic acid residues in proteins, and with
phosphates and bases in DNA/RNA; thus stabilizing elements of
protein structure has been widely observed.
In addition, arginine is frequently found alongside cleavage sites
of substrates and inhibitors of trypsin-like serine proteases, such
as thrombin, Factor Xa, and Dengue NS3 protease,1 and also in
novel antagonists of G Protein-Coupled Receptors such as the
plasma protein C5a.2
1.Brinkworth, R.I., Fairlie, D.P., Leung, D., and Young, P.R., Journal of General Virology, 1999, 80, 1167.
2.Finch, A. M.; Wong, A. K.; Wadi, S. K.; Paczkowski, N. J.; Fairlie, D. P.; Taylor, S. M. J. Med. Chem. 1999, 42, 1965.
The highly polar and charged side chain of arginine is often
an undesirable feature in drug design and discovery programs.
Problems with bioavailability and poor membrane
permeability have historically resulted in poor progression of
the thousands of known enzyme inhibitors into the clinic and
as human therapeutics.3
Arginine also possesses a highly flexible sidechain, which
may require the expenditure of energy to adopt an enzyme-
binding configuration.
Arginine displays complex side-reactions in solution-phase
syntheses, complicating product outcomes and purification
procedures.
The problem
3.  Leung, D., Abbenante, G, and Fairlie, D.P., J. Med. Chem., 2000, 43, 305.
Binding Modes of Arginine
Protein-Protein binding
Protein-DNA/RNA binding
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By reducing the pKa of the 
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hydrophobicity and 
membrane permeability for 
a series of isosteric
arginine mimetics can be 
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pKa 7.9
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pKa 12.3
Citrull ine (Cit)
pKa 0.2
Modification of side chain hydrophobicity 
Thrombin-like serine protease inhibitors have traditionally involved the use of a
peptide fragment derived from the P1-P3 sequence of endogenous substrates,
with the scissile bond being replaced with an electrophilic isostere such as
aldehyde or trifluoromethyl ketones.
Extensive work in our laboratories and others, is being directed towards the
synthesis of compounds with more rigid and hydrophobic side chains and also
to the synthesis of arginine mimetics lacking electrophilic isosteres.
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Crystal Structure of Dengue NS3 Protease 
with bound Bowman-Birk Inhibitor
Inhibitor contains an arginine in two
equally populated states; hydrogen
bonding to serine and tyrosine residues
in one form and in a “traditional” Type 2
bonding arrrangement with an aspartate
residue in the other
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Applications: HIV-REV
HIV-1 Rev is a 116 amino acid RNA-
binding protein, that is responsible for
transport of viral mRNA from the host
nucleus to the cytoplasm. The binding
domain consists of a core of 17 residues, 10
of which are Arginine.
One project within our group entails
systematically altering the arginine residues
within the binding domain to ultimately
produce an inhibitor with improved
membrane permeability. Such an inhibitor
should prevent replication of HIV in infected
human cells.
Scanlon, M. J. et al., Biochemistry 1995, 34, 8242-8249.
Bonding of Rev34-50 to RNA
Applications: C5a Antagonists
C5a is a 74 residue complement protein which is synthesized in human blood in
response to infection. The interaction between C5a (in the blood) and its receptor
on the surface of numerous types of cells leads to production of many cytokines
and inflammatory mediators which contribute to autoimmune and inflammatory
diseases such as rheumatoid arthritis, lupus, asthma, ischemia and reperfusion
injury and at least 20 other inflammatory conditions. Cyclic hexapeptides have
been shown in our laboratory to be potent, orally available antagonists of the C5a
receptor, a member of the G Protein-Coupled receptor family. We are in the
process of examining the effect on bioavailability of analogues bearing arginine
mimetics.
Finch, A. M.; et al.,  J. Med. Chem. 1999, 42, 1965-1974.
